Cargando…

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus

Detalles Bibliográficos
Autores principales:	Lopeman, Rose C., Harrison, James, Rathbone, Daniel L., Desai, Maya, Lambert, Peter A., Cox, Jonathan A. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058606/ https://www.ncbi.nlm.nih.gov/pubmed/32139840 http://dx.doi.org/10.1038/s41598-020-61546-6

Ejemplares similares

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex
por: Harrison, James, et al.
Publicado: (2021)

Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare
por: Lopeman, Rose C., et al.
Publicado: (2019)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin
por: Beech, Alison J., et al.
Publicado: (2023)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
por: Campanella, Toni A, et al.
Publicado: (2020)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
por: Kurihara, Dai, et al.
Publicado: (2022)

Author Correction: Lactate oxidation facilitates growth of Mycobacterium tuberculosis in human macrophages
por: Billig, Sandra, et al.
Publicado: (2018)

Author Correction: System OMICs analysis of Mycobacterium tuberculosis Beijing B0/W148 cluster
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Author Correction: Genomic epidemiology of Mycobacterium tuberculosis in Santa Catarina, Southern Brazil
por: Verza, Mirela, et al.
Publicado: (2020)

Author Correction: Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan
por: Khan, Anwar Sheed, et al.
Publicado: (2021)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
por: Young, Katherine, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
por: Bhagunde, Pratik, et al.
Publicado: (2019)

Author Correction: A comprehensive update to the Mycobacterium tuberculosis H37Rv reference genome
por: Chitale, Poonam, et al.
Publicado: (2022)

2806. The Mechanism of β-Lactam Antibiotic Action: Structural Analysis of Mycobacterium abscessus l,d-Transpeptidases, d,d-Carboxypeptidase and penicillin-binding-proteins binding by imipenem, ceftaroline, and amoxicillin
por: Shin, Eunjeong, et al.
Publicado: (2023)

Author Correction: Extensive genomic diversity among Mycobacterium marinum strains revealed by whole genome sequencing
por: Das, Sarbashis, et al.
Publicado: (2020)

Author Correction: Sex differences in the C57BL/6 model of Mycobacterium tuberculosis infection
por: Dibbern, Jannike, et al.
Publicado: (2018)

Correction: MabsBase: A Mycobacterium abscessus Genome and Annotation Database
por: Heydari, Hamed, et al.
Publicado: (2013)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Author Correction: Genetic basis of hypercholesterolemia in adults
por: Saadatagah, Seyedmohammad, et al.
Publicado: (2021)

Author Correction: Establishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosis
por: Singh, Mamta, et al.
Publicado: (2020)

Author Correction: Artificial Intelligence and Machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis
por: Jamal, Salma, et al.
Publicado: (2020)

Author Correction: Establishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosis
por: Singh, Mamta, et al.
Publicado: (2021)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023)

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
por: Brown, Michelle L, et al.
Publicado: (2020)

Author Correction: Dynamic patterning of microparticles with acoustic impulse control
por: Cox, Luke, et al.
Publicado: (2023)

Correction to: Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
Publicado: (2023)

Author’s Correction
Publicado: (2012)

Author’s Correction
Publicado: (2013)

Author Correction
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0i0cuhjrpoptlk9b1v65r6mcf1